Decision support methods for the detection of adverse events in post-marketing data.
about
Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactionsUseful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal DetectionTorsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropeAssociation Patterns in Open Data to Explore Ciprofloxacin Adverse EventsComputational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworksNovel data-mining methodologies for adverse drug event discovery and analysisPharmacovigilance Using Clinical NotesMultinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases.Data mining of the public version of the FDA Adverse Event Reporting SystemSignal detection and monitoring based on longitudinal healthcare dataCommonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method.Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.Exploitation of semantic methods to cluster pharmacovigilance termsSimilarity-based modeling applied to signal detection in pharmacovigilance.Mining adverse drug reactions from online healthcare forums using hidden Markov modelAutomatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives.3D pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance.Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection.Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies.Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics.Evaluation of automated term groupings for detecting anaphylactic shock signals for drugs.Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactionsPredicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network.A survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms.Detection of pharmacovigilance-related adverse events using electronic health records and automated methods.Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition.Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilanceLinking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndromeLongitudinal medical records as a complement to routine drug safety signal analysis.Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactions.Anticipating drug side effects by comparative pharmacology.Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.Extraction of potential adverse drug events from medical case reports.Detecting Signals of Disproportionate Reporting from Singapore's Spontaneous Adverse Event Reporting System: An Application of the Sequential Probability Ratio Test.Decision making in drug safety-a literature review of criteria used to prioritize newly detected safety issues.Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.
P2860
Q26743858-CDD7572C-AD4B-45EE-A05F-78B32ECE77C0Q27335410-159BC976-72F9-4C66-887D-B75C6E57985EQ28535299-42B51C5F-78B0-440F-B7A7-61B93E2EE5F1Q28602965-60382924-F228-4B9F-84DE-1A659B852D39Q28651547-26418C41-857B-484D-AB5C-9554F94DA9D6Q28681788-75547E50-6DA0-4857-A28E-CD023405DEA6Q30058397-451773CB-F494-4479-BD76-DE048C537971Q30573306-0C473007-65A7-42CA-9180-5C159E75FC61Q30651235-91B47EFA-F15C-4CE6-8A75-FEF9BA5DF71FQ30706851-BEFF29EB-6F94-44A5-A2E9-58512FC214ABQ30790443-5C69686D-12D9-4903-9CF7-CF4A5788534CQ31149096-E89BE737-A974-48B0-838C-A47BFA6C2318Q33535332-463E5F04-769F-40BD-B7C1-AC5B3C3CD0CAQ33681951-5C2D8608-408F-4807-9770-B8F17061273BQ33715057-30AE53E2-4559-4BB7-96B5-BFFF0CCC6254Q34413023-1AE90285-10BB-4CCA-B7EC-3446E602896BQ34812232-8F34500E-43B0-4960-AD7E-E1CA75E194C5Q34881857-954B5BA4-4F35-4596-B575-766C6272DB01Q35153278-414159EA-E2C2-4E1B-BA29-EA86763C318CQ36161996-2C1E5FDA-15BA-466E-A2BB-5870B1CF7EDBQ36205253-3DA87B35-EB69-4BB8-A62F-C89B4093774BQ36229893-0B16748D-C70F-4F8B-8F39-C747530331ACQ36519210-4AB419E7-E386-437B-924E-053A0C701006Q36771112-3D7E2506-A5AE-4CC1-9BDD-353A721C06E9Q36853573-950FDB98-7ADF-4D87-8863-DF9A47096454Q36909828-37E04147-8679-4782-A47D-5EBDA182748EQ36936563-38A9563B-EFB6-45B7-934E-6DD8ABA7A35FQ36953107-0ED28B51-F989-4ED2-BD72-16AFBD6F123AQ36967198-B16E2A71-0E6A-44E6-8F3A-57FEEDDDF5D4Q37257186-92DC79FE-9814-4B60-982B-6213547CA071Q37257431-43FB2E55-5E09-4FA1-82FC-61A7882C864EQ37378299-F9D1D22D-FD6A-47C5-9F01-123574380A6AQ37632247-F323B3C7-EFA2-4000-BF02-A34DE8E60890Q37775961-2036B788-92EF-4D67-90B5-571C26F9451DQ38264389-554DC94A-9A04-4B82-A3ED-6BE09D0B6529Q38459298-B5D3C5DD-02C9-49F9-A338-F4ECE9FE053EQ38937775-4820FCE9-230A-4F0D-ABAD-43F0FBD40FF4Q39017851-1A3FD7EE-1FDE-4287-92D8-0AED8A9524F1Q39133567-45FF4EAA-FDC6-48F1-9C50-F8D0C9E75116Q39794630-1721946B-306F-42A2-8F97-7FC93F40696C
P2860
Decision support methods for the detection of adverse events in post-marketing data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Decision support methods for the detection of adverse events in post-marketing data.
@ast
Decision support methods for the detection of adverse events in post-marketing data.
@en
type
label
Decision support methods for the detection of adverse events in post-marketing data.
@ast
Decision support methods for the detection of adverse events in post-marketing data.
@en
prefLabel
Decision support methods for the detection of adverse events in post-marketing data.
@ast
Decision support methods for the detection of adverse events in post-marketing data.
@en
P1433
P1476
Decision support methods for the detection of adverse events in post-marketing data.
@en
P304
P356
10.1016/J.DRUDIS.2008.12.012
P577
2009-01-31T00:00:00Z